Clinical and genomic alternations predictive of response to sunitinib in patients with advanced renal cell carcinoma.
e16109Background: Sunitinib is a 1st-line therapy for clear cell Renal Cell Carcinoma (ccRCC); however, 20-30% of tumors show primary resistant disease with progression as the best response. This s...